Purchase this article with an account.
N. Umeda, S. Kachi, H. Akiyama, G. Zahn, R. Stragies, P.A. Campochiaro; Suppression and Regression of Choroidal Neovascularization by Systemic Administration of an 5ß1 Integrin Antagonist . Invest. Ophthalmol. Vis. Sci. 2006;47(13):899.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Integrin α5ß1 plays an important role in developmental angiogenesis, but its role in various types of pathologic neovascularization has not been completely defined.
The effect of JSM6427, a selective α5ß1 antagonist, was quantitatively assessed in mice with choroidal neovascularization due to laser–induced rupture of Bruch's membrane.
In this study, we found strong upregulation of α5ß1 in choroidal neovascularization. Implantation of an osmotic pump delivering 1.5 or 10 µ/hour (∼1.8 or 12 mg/kg/day) of JSM6427 caused significant suppression of choroidal neovascularization; the area of neovascularization was reduced by 33 to 40%. When an osmotic pump delivering 10 µg/hour of JSM6427 was implanted 7 days after rupture of Bruch's membrane, there was TUNEL staining in vascular cells within the neovascularization and significant regression of the neovascularization over the next week.
These data suggest that α5ß1 plays a role in the development and maintenance of choroidal neovascularization and provides a target for therapeutic intervention.
This PDF is available to Subscribers Only